COMBINATION THERAPY FOR CHRONIC RECURRENT VERTEBROGENIC PAIN SYNDROME
- 作者: Solovyeva E.1, Ivanokov A.1, Manevsky A.1
-
隶属关系:
- Russian National Research Medical University
- 期: 卷 23, 编号 5 (2012)
- 页面: 43-48
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115459
- ID: 115459
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Due to its high analgesic effect, combination therapy for chronic musculoskeletal pain syndromes with the nonsteroidal anti-inflammatory drug (NSAID) Mesipol (Meloxicam) with the central myorelaxant Baclosan (Baclofen) can more promptly achieve significant analgesia and reduce the duration of medicamentous therapy and a risk of NSAID-associated side effects.
全文:
作者简介
E. Solovyeva
Russian National Research Medical University
Email: ellasolovieva@yandex.ru
Professor, MD
A. Ivanokov
Russian National Research Medical UniversityMD
A. Manevsky
Russian National Research Medical UniversityMD
参考
- Atkinson J. Chronic back pain: searching for causes and cures // J. Rheumatol. - 2004; 31: 2323-5.
- Черненко О.А. Клинические и МР-томографические характеристики вертеброневрологических нарушений в различных возрастных группах. -Автореф. дис. ... канд. мед. наук. - 1996.
- Алексеев В.В. Диагностика и лечение болей в пояснице, вызванных компрессионной радикулопатией // Справ. поликлинич. врача. - 2002; 4: 23-30.
- Андреев В.В. О нейрохимических механизмах болеутоляющего действия ГАМК-позитивных препаратов // Нейропсихофармакология болеутоляющих средств. - Л.: 1986; с. 75-86.
- Slonimski M., Abram S., Zuniga R. Intrathecal baclofen in pain management // Reg. Anesth. Pain. Med. - 2004; 29 (3): 269-76.
- Насонов Е.Л. Применение нестероидных противовоспалительных препаратов: терапевтические перспективы // РМЖ. - 2002; 10 (4): 206-12.
- Caldwell B., Aldington S., Shirtcliffe P. et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis // J. R. Soc. Med. - 2006; 99: 132-40.
- McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase // JAMA. - 2006; 13 (296): 1-12.
- Doc. Ref. EMEA/413136. - 2006.
- Euller-Ziegler L.,Velicitat P., Bluhmki E. et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration // Inflamm. Res. - 2001; 50 (1): 5-9.
- Zeidler H., Kaltwasser J., Leonard J. et al. Prescription and Tolerability of Meloxicam in Day-to-Day Practice: Postmarketing Observational Cohort Study of 13 307 Patients.
- Davies N., Skjodt N. Clinical pharmacokinetics of meloxicam: a cyclooxygenase-2 preferential non-steroidal anti-inflammatory drug // Clin. Pharmacokinet. - 1999; 36: 115-26.
- Цветкова Е.С., Панасюк Е.Ю., Иониченок Н.Г. и др. Перспективы применения ингибиторов циклооксигеназы-2 при остеоартрозе // Consilium Medicum. - 2004; 6 (2): 100-5.
- Dequeker J., Hawkey С., Kahan A. et al. Improvement in gastrointestinal tolerability on the selective cyclooxygenase (COX)-2 inhibitor meloxicam, compared with piroxicam: results of the safety and Efficacy Large scale Evalution of COX inhibiting Therapies (SELECT) trial in osteoarthritis // Br. J. Rheaumatol. - 1998; 37: 946-51.
- Hawkey С., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large Scale International Study Safety Assessment // Br. J. Rheaumatol. - 1988; 37: 937-45.
- Singh G., Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complication: pooled analysis of 27039 patients: the results of the IMPROVE trial // EULAR Congress, Prague. - 2001.
- Combe B., Velicitat P., Garson N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients // Inflamm. Res. - 2001; 50 (Suppl. 1): 10-6.
- Vidal L., Kneer W., Baturone M. et al. Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder // Inflam. Res. - 2001; 50 (Suppl. 1): 24-9.
- Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях // Тер. арх. -2004; 12: 78-80.
- Алексеев В.В. Применение мелоксикама в лечении люмбоишалгического синдрома // РМЖ. - 2003; 7 (11): 416-8.
补充文件
